Article
Tamoxifen-stimulated growth of breast cancer due to p21 loss
27 Dec 2007
Abstract excerpt
Tamoxifen is widely used for the treatment of hormonally responsive breast cancers. However, some resistant breast cancers develop a growth proliferative response to this drug, as evidenced by tumor regression upon its withdrawal. To elucidate the molecular mediators of this paradox, tissue samples from a patient with tamoxifen-stimulated breast cancer were analyzed. These studies revealed that loss of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
